The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly.

Eli Lilly raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss ...

Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate ...

Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong appetite for its widely popular weight-loss ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...

Drug company Eli Lilly and NVIDIA announced a new partnership to build a supercomputer for drug research. Drug manufacturer ...

Eli Lilly and computing giant Nvidia are teaming up to build a new supercomputer that the pair say will be the most powerful owned and operated by a pharmaceutical company.

Speedskater Erin Jackson spoke about living with eczema. By registering you consent to the collection and use of your information to provide the products and services you have requested from us and as ...

Mounjaro and Zepbound have helped boost the company's market cap. New data indicate these drugs do more than just help patients lose weight, contributing to potentially lowering risks to hearts and ...

Healthcare is underowned; 2026 rate cuts and policy clarity should trigger inflows. As XLV’s largest weight and obesity leader, Lilly will capture outsized demand during the sector re-rating cycle.